Purpose This study evaluated the efficacy and safety of pemetrexed, carboplatin, and
bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with …

Introduction There is no consensus chemotherapy regimen with concurrent radiotherapy
(RT) for inoperable stage IIIA/B non–small-cell lung cancer. This trial evaluated pemetrexed …

Standard platinum-based chemotherapy combinations for advanced non–small-cell lung
cancer (NSCLC) have reached a plateau in terms of the survival benefit they offer for …

The present study evaluated the efficacy and safety of pemetrexed, carboplatin and
bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy …

Objectives Retrospective subgroup analysis in JMDB study indicates that the between-arm
differences in overall survival (OS) in the East Asian subgroup were consistent with those …

Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthetase and other
folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin …

Background: Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC)
improves survival modestly but new strategies are needed. This trial was designed to …

Background Pemetrexed has emerged as one of the most active agents for the treatment of
patients with advanced non-small cell lung cancer (NSCLC). We conducted a phase II study …

Current standard for locally advanced non-small cell lung cancer (NSCLC) is combined
concurrent therapy with a platinum-based regimen. Preclinical synergistic activity of …

8060 Background: Cytotoxic chemotherapy seeks to reduce or stabilize tumor burden in
advanced non-small cell lung cancer (NSCLC). Administration, however, is limited by …